当前位置：
X-MOL 学术
›
J. Neuroimmunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-08-01 , DOI: 10.1016/j.jneuroim.2020.577289 Li Chengyu 1 , Shi Weixiong 1 , Chen Chao 1 , Liu Songyan 2 , Sang Lin 3 , Zheng Zhong 3 , Pan Hua 1 , Jian Fan 1 , Chen Na 1 , Cui Tao 1 , Wu Jianwei 1 , Ren Haitao 4 , Guan Hongzhi 4 , Shao Xiaoqiu 1
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-08-01 , DOI: 10.1016/j.jneuroim.2020.577289 Li Chengyu 1 , Shi Weixiong 1 , Chen Chao 1 , Liu Songyan 2 , Sang Lin 3 , Zheng Zhong 3 , Pan Hua 1 , Jian Fan 1 , Chen Na 1 , Cui Tao 1 , Wu Jianwei 1 , Ren Haitao 4 , Guan Hongzhi 4 , Shao Xiaoqiu 1
Affiliation
|
We described the clinical and neuroimaging characteristics of seven Chinese patients with anti-GAD65 antibody-associated neurological disorders of whom epileptic seizures were the initial and main symptoms. All patients were given immunotherapy and followed up monthly. The outcome demonstrates that immunotherapy is helpful for non-seizure manifestations of anti-GAD65-associated neurological autoimmunity and is less effective in the treatment of seizures, yet partial responses can still occur in the early stage. Taken together we suggest a trial with immunotherapy in all patients in the early stage of the disease, and in patients with non-epilepsy symptoms in the later stage.
更新日期：2020-08-01
京公网安备 11010802027423号